CSF3 and cancer: The national cancer center network (NCCN) guideline on managing febrile neutropenia (FN) recommends prophylactic treatment of granulocyte colony–stimulating factor (G-CSF) for patients receiving chemotherapy and at high risk of more than 20% of developing FN.